Xiaoyan Zhong1, Dan Lai2, Yun Ye1, Xuping Yang1, Bin Yu3, Yilan Huang4. 1. Department of Pharmacy, The Affiliated Hospital of Luzhou Medical College, Luzhou, 646000, Sichuan Province, People's Republic of China. 2. Department of ENT, The Affiliated Hospital of Luzhou Medical College, Luzhou, 646000, Sichuan Province, People's Republic of China. 3. College of Pharmacy, Sichuan Medical University, Luzhou, 646000, Sichuan Province, People's Republic of China. 4. Department of Pharmacy, The Affiliated Hospital of Luzhou Medical College, Luzhou, 646000, Sichuan Province, People's Republic of China. hyl3160131@163.com.
Abstract
PURPOSE: To assess the efficacy and safety of empagliflozin (EMPA) as add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM). METHODS: We searched PubMed, Embase, Medline, OVID, Cochrane Library and Web of Science. Randomized controlled trials of EMPA as add-on to MET for T2DM were included. Two investigators independently selected studies, extracted data and assessed the risk of bias. A meta-analysis was conducted by using RevMan 5.3 software and Stata 12 software. RESULTS: Seven trials including 4256 patients were analysed. Compared with placebo, two different doses of EMPA significantly reduced glycated haemoglobin (HbA1c) [10 mg: weighted mean difference (WMD) -0.57 %; 95 % confidence interval (CI) -0.65 to -0.49 %, P < 0.00001; 25 mg: WMD -0.65 %; 95 % CI -0.72 to -0.57 %, P < 0.00001]. Compared with active comparators (two sitagliptin, one linagliptin and one glimepiride), 10 mg of EMPA provided a similar reduction in HbA1c [WMD -0.10 %; 95 % CI -0.23 to 0.03 %, P = 0.13], while 25 mg of EMPA provided a significantly greater reduction in HbA1c [WMD -0.13 %; 95 % CI -0.20 to -0.06 %, P = 0.0005]. In addition, EMPA as add-on to MET also had a favourable effect on body weight and blood pressure. The risk of hypoglycaemia in the EMPA group was similar to the placebo group or active comparator group. CONCLUSIONS: EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. However, high-quality trials with large samples are still needed in order to confirm their long-term safety.
PURPOSE: To assess the efficacy and safety of empagliflozin (EMPA) as add-on to metformin (MET) in patients with type 2 diabetes mellitus (T2DM). METHODS: We searched PubMed, Embase, Medline, OVID, Cochrane Library and Web of Science. Randomized controlled trials of EMPA as add-on to MET for T2DM were included. Two investigators independently selected studies, extracted data and assessed the risk of bias. A meta-analysis was conducted by using RevMan 5.3 software and Stata 12 software. RESULTS: Seven trials including 4256 patients were analysed. Compared with placebo, two different doses of EMPA significantly reduced glycated haemoglobin (HbA1c) [10 mg: weighted mean difference (WMD) -0.57 %; 95 % confidence interval (CI) -0.65 to -0.49 %, P < 0.00001; 25 mg: WMD -0.65 %; 95 % CI -0.72 to -0.57 %, P < 0.00001]. Compared with active comparators (two sitagliptin, one linagliptin and one glimepiride), 10 mg of EMPA provided a similar reduction in HbA1c [WMD -0.10 %; 95 % CI -0.23 to 0.03 %, P = 0.13], while 25 mg of EMPA provided a significantly greater reduction in HbA1c [WMD -0.13 %; 95 % CI -0.20 to -0.06 %, P = 0.0005]. In addition, EMPA as add-on to MET also had a favourable effect on body weight and blood pressure. The risk of hypoglycaemia in the EMPA group was similar to the placebo group or active comparator group. CONCLUSIONS:EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. However, high-quality trials with large samples are still needed in order to confirm their long-term safety.
Entities:
Keywords:
Empagliflozin; Meta-analysis; Metformin; Systematic review; Type 2 diabetes
Authors: Despoina Vasilakou; Thomas Karagiannis; Eleni Athanasiadou; Maria Mainou; Aris Liakos; Eleni Bekiari; Maria Sarigianni; David R Matthews; Apostolos Tsapas Journal: Ann Intern Med Date: 2013-08-20 Impact factor: 25.391
Authors: A Liakos; T Karagiannis; E Athanasiadou; M Sarigianni; M Mainou; K Papatheodorou; E Bekiari; A Tsapas Journal: Diabetes Obes Metab Date: 2014-05-28 Impact factor: 6.577
Authors: J Rosenstock; L J Seman; A Jelaska; S Hantel; S Pinnetti; T Hach; H J Woerle Journal: Diabetes Obes Metab Date: 2013-08-22 Impact factor: 6.577
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2015-01 Impact factor: 19.112
Authors: Seung Hyun Ko; Kyu Yeon Hur; Sang Youl Rhee; Nan Hee Kim; Min Kyong Moon; Seok O Park; Byung Wan Lee; Hyun Jin Kim; Kyung Mook Choi; Jin Hwa Kim Journal: Diabetes Metab J Date: 2017-10 Impact factor: 5.376